Wellington Management Group LLP Trims Stock Position in Savara Inc. $SVRA

Key Points

• Wellington Management Group LLP reduced its stock position in Savara Inc. by 24.1%, selling over 1.3 million shares, which leaves them with approximately 4.16 million shares valued at $11.53 million.
• Savara's stock recently opened at $3.29 and is experiencing a downward trend with a 52-week range of $1.89 to $4.70.
• Analysts have mixed opinions on Savara's stock, with target prices ranging from $2.00 to $8.00, reflecting varied ratings from "buy" to "in-line."

Wellington Management Group LLP lessened its holdings in shares of Savara Inc. (NASDAQ:SVRA - Free Report) by 24.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,162,653 shares of the company's stock after selling 1,319,001 shares during the period. Wellington Management Group LLP owned approximately 2.41% of Savara worth $11,531,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in SVRA. Wells Fargo & Company MN raised its holdings in shares of Savara by 42.9% during the fourth quarter. Wells Fargo & Company MN now owns 59,277 shares of the company's stock worth $182,000 after purchasing an additional 17,786 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Savara during the fourth quarter worth $798,000. Barclays PLC raised its holdings in shares of Savara by 2.5% during the fourth quarter. Barclays PLC now owns 236,705 shares of the company's stock worth $728,000 after purchasing an additional 5,700 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Savara during the fourth quarter worth $34,000. Finally, Marshall Wace LLP purchased a new position in shares of Savara during the fourth quarter worth $1,109,000. Hedge funds and other institutional investors own 87.93% of the company's stock.

Savara Stock Down 0.6%

Shares of NASDAQ SVRA opened at $3.29 on Thursday. The company's 50-day simple moving average is $2.54 and its 200-day simple moving average is $2.68. Savara Inc. has a 52-week low of $1.89 and a 52-week high of $4.70. The firm has a market cap of $568.64 million, a price-to-earnings ratio of -6.58 and a beta of 0.40. The company has a quick ratio of 11.08, a current ratio of 11.08 and a debt-to-equity ratio of 0.25.

Savara (NASDAQ:SVRA - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02). Equities analysts predict that Savara Inc. will post -0.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SVRA. Evercore ISI dropped their price target on shares of Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a research report on Wednesday, May 28th. Oppenheimer raised their price target on shares of Savara from $5.00 to $6.00 and gave the company an "outperform" rating in a research report on Friday, August 15th. HC Wainwright upgraded shares of Savara from a "neutral" rating to a "buy" rating and raised their price target for the company from $2.00 to $5.00 in a research report on Friday, August 15th. Wells Fargo & Company dropped their price target on shares of Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 28th. Finally, Guggenheim restated a "buy" rating and set a $8.00 price target (down previously from $9.00) on shares of Savara in a research report on Wednesday, May 28th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $6.17.

Insider Buying and Selling at Savara

In other Savara news, Director Richard J. Hawkins purchased 48,225 shares of the firm's stock in a transaction dated Friday, June 20th. The shares were purchased at an average cost of $2.04 per share, with a total value of $98,379.00. Following the completion of the purchase, the director owned 115,466 shares in the company, valued at approximately $235,550.64. This represents a 71.72% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 5.33% of the company's stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.